These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

540 related items for PubMed ID: 15068399

  • 1. Nonparametric population modeling of valproate pharmacokinetics in epileptic patients using routine serum monitoring data: implications for dosage.
    Bondareva IB, Jelliffe RW, Sokolov AV, Tischenkova IF.
    J Clin Pharm Ther; 2004 Apr; 29(2):105-20. PubMed ID: 15068399
    [Abstract] [Full Text] [Related]

  • 2. Population pharmacokinetic modelling of carbamazepine in epileptic elderly patients: implications for dosage.
    Bondareva IB, Jelliffe RW, Gusev EI, Guekht AB, Melikyan EG, Belousov YB.
    J Clin Pharm Ther; 2006 Jun; 31(3):211-21. PubMed ID: 16789986
    [Abstract] [Full Text] [Related]

  • 3. Predictability of individualized dosage regimens of carbamazepine and valproate mono- and combination therapy.
    Bondareva IB, Jelliffe RW, Andreeva OV, Bondareva KI.
    J Clin Pharm Ther; 2011 Oct; 36(5):625-36. PubMed ID: 21062333
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Development of a population pharmacokinetic model for carbamazepine based on sparse therapeutic monitoring data from pediatric patients with epilepsy.
    Carlsson KC, Hoem NO, Glauser T, Vinks AA.
    Clin Ther; 2005 May; 27(5):618-26. PubMed ID: 15978311
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Pharmacokinetic modeling of valproate from clinical data in Serbian epileptic patients.
    Jankovic SM, Milovanovic JR.
    Methods Find Exp Clin Pharmacol; 2007 Dec; 29(10):673-9. PubMed ID: 18200330
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Population pharmacokinetics of valproate in Chinese children with epilepsy.
    Jiang DC, Wang L, Wang YQ, Li L, Lu W, Bai XR.
    Acta Pharmacol Sin; 2007 Oct; 28(10):1677-84. PubMed ID: 17883957
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Population pharmacokinetic modelling of carbamazepine by using the iterative Bayesian (IT2B) and the nonparametric EM (NPEM) algorithms: implications for dosage.
    Bondareva IB, Sokolov AV, Tischenkova IF, Jelliffe RW.
    J Clin Pharm Ther; 2001 Jun; 26(3):213-23. PubMed ID: 11422606
    [Abstract] [Full Text] [Related]

  • 12. Population pharmacokinetics of steady-state carbamazepine in Egyptian epilepsy patients.
    El Desoky ES, Sabarinath SN, Hamdi MM, Bewernitz M, Derendorf H.
    J Clin Pharm Ther; 2012 Jun; 37(3):352-5. PubMed ID: 21883329
    [Abstract] [Full Text] [Related]

  • 13. Poor applicability of estimation method for adults to calculate unbound serum concentrations of valproic acid in epileptic neonates and infants.
    Ueshima S, Aiba T, Ishikawa N, Sato T, Kawasaki H, Kurosaki Y, Ohtsuka Y, Sendo T.
    J Clin Pharm Ther; 2009 Aug; 34(4):415-22. PubMed ID: 19583674
    [Abstract] [Full Text] [Related]

  • 14. Pharmacokinetic characteristics of a new multiple unit sustained release formulation of sodium valproate.
    Wangemann M, Retzow A, Vens-Cappell B.
    Int J Clin Pharmacol Ther; 1999 Feb; 37(2):100-8. PubMed ID: 10082174
    [Abstract] [Full Text] [Related]

  • 15. The influence of old age and enzyme inducing comedication on the pharmacokinetics of valproic acid at steady-state: A case-matched evaluation based on therapeutic drug monitoring data.
    Fattore C, Messina S, Battino D, Croci D, Mamoli D, Perucca E.
    Epilepsy Res; 2006 Aug; 70(2-3):153-60. PubMed ID: 16730950
    [Abstract] [Full Text] [Related]

  • 16. Pharmacokinetic variability of nimodipine disposition after single and multiple oral dosing to hypertensive renal failure patients: parametric and nonparametric population analysis.
    Terziivanov D, Atanasova I, Dimitrova V, Robeva R, Unger S, Mück W.
    Int J Clin Pharmacol Ther; 1999 Aug; 37(8):404-12. PubMed ID: 10475143
    [Abstract] [Full Text] [Related]

  • 17. A population pharmacokinetic model of valproic acid in pediatric patients with epilepsy: a non-linear pharmacokinetic model based on protein-binding saturation.
    Ding J, Wang Y, Lin W, Wang C, Zhao L, Li X, Zhao Z, Miao L, Jiao Z.
    Clin Pharmacokinet; 2015 Mar; 54(3):305-17. PubMed ID: 25388986
    [Abstract] [Full Text] [Related]

  • 18. Population pharmacokinetics of levetiracetam and dosing recommendation in children with epilepsy.
    Chhun S, Jullien V, Rey E, Dulac O, Chiron C, Pons G.
    Epilepsia; 2009 May; 50(5):1150-7. PubMed ID: 19175400
    [Abstract] [Full Text] [Related]

  • 19. A limited sampling strategy for estimating individual pharmacokinetic parameters of coagulation factor VIII in patients with hemophilia A.
    Bolon-Larger M, Chamouard V, Bressolle F, Boulieu R.
    Ther Drug Monit; 2007 Feb; 29(1):20-6. PubMed ID: 17304146
    [Abstract] [Full Text] [Related]

  • 20. Valproic acid clearance in children with epilepsy.
    Sánchez-Alcaraz A, Quintana MB, López E, Rodríguez I.
    J Clin Pharm Ther; 1998 Feb; 23(1):31-4. PubMed ID: 9756109
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.